<DOC>
	<DOC>NCT02399202</DOC>
	<brief_summary>To characterize the pharmacokinetics of LCI699 following a single oral dose in adult subjects with various degrees of impaired renal function.</brief_summary>
	<brief_title>A Phase I Study of Osilodrostat (LCI699) in Healthy Volunteers and Subjects With Impaired Renal Function</brief_title>
	<detailed_description />
	<mesh_term>Renal Insufficiency</mesh_term>
	<criteria>Weight must be â‰¥50 kg and BMI must be between 1835 kg/m2 Subjects must have stable renal disease without evidence of progressive decline in renal function (stable renal disease is defined as no significant change, such as, stable eGFR &lt;90 mL/min, for 12 weeks prior to study entry) Other than renal impairment, subjects must be stable and appropriately managed relative to chronic diseases (such as diabetes and hypertension) History of any surgical or medical condition other than renal impairment which might significantly alter the absorption, distribution, metabolism or excretion of drugs. Subjects with ongoing alcohol or drug abuse within 1 month prior to dosing or evidence of such abuse as indicated by the laboratory assays conducted during the screening or baseline evaluations. Subjects with screening 12lead ECG QTcF of &gt; 450 msec for males or &gt; 460 msec for female History of diabetes mellitus (Type 1 or 2) or blood glucose of &gt;125 mg/dl at screening Subjects with potassium levels greater than the upper limit of normal (&gt;ULN) Other protocol defined Inclusion/Exclusion may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Renal impairment, osilodrostat, LCI699</keyword>
</DOC>